A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin + Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non-Small Cell Lung Cancer with EGFR sensitive mutations - LOGIK1302

Trial Profile

A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin + Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non-Small Cell Lung Cancer with EGFR sensitive mutations - LOGIK1302

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2016

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LOGIK1302
  • Most Recent Events

    • 25 Oct 2013 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 20 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top